MDM2 Gene Function
MDM2 Proto-Oncogene
Overview
MDM2 is the primary negative regulator of p53, acting as an E3 ubiquitin ligase that targets p53 for proteasomal degradation. MDM2 amplification is a mechanism of p53 pathway inactivation in wild-type TP53 tumors.
Molecular Mechanism
Mechanism Summary
MDM2 is the principal E3 ubiquitin ligase for p53. It binds p53 transactivation domain, blocks transcription, and polyubiquitinates p53 Lys residues for proteasomal degradation. MDM2 is itself a p53 transcriptional target, forming a negative feedback loop.
Step-by-Step Mechanism
Under non-stressed conditions, MDM2 RING domain binds p53 N-terminal transactivation domain at the Phe19, Trp23, Leu26 'hydrophobic cleft', masking the transactivation domain and blocking co-activator (p300/CBP) interaction.
MDM2 simultaneously acts as an E3 ubiquitin ligase, polyubiquitinating p53 at C-terminal lysine residues (Lys370, Lys372, Lys373, Lys381, Lys382, Lys386), targeting p53 for CRM1-mediated nuclear export and 26S proteasomal degradation.
MDM4 (MDMX) — a structurally related protein lacking E3 ligase activity — directly inhibits p53 transcriptional activity and forms heterodimers with MDM2, increasing MDM2-mediated p53 degradation.
MDM2 inhibitors (idasanutlin, milademetan) occupy p53's hydrophobic cleft binding site on MDM2, mimicking p53 structure and blocking the MDM2–p53 interaction, stabilising p53 in TP53-wild-type tumours.
Upstream Regulators
p53 transcriptionally activates MDM2 promoter, creating the p53-MDM2 negative feedback loop
Phosphorylates MDM2 Ser166/Ser186, promoting nuclear localisation and enhanced p53 degradation
Sequesters MDM2 in nucleolus via NoLS binding, preventing p53 ubiquitination
Downstream Targets
Proteasomal degradation of p53; p53 pathway suppression
MDM2 binds and ubiquitinates pRb, promoting its degradation in a p53-independent manner
MDM2 targets additional substrates relevant to DNA repair and epithelial phenotype
Key Post-Translational Modifications
Nuclear entry; enhanced p53 degradation; pro-survival signal
Impairs MDM2 function; allows p53 stabilisation after DNA damage
MDM2 self-degradation; fine-tunes MDM2 levels
Disease Mechanism
MDM2 amplification is the dominant mechanism of p53 pathway inactivation in tumours that retain wild-type TP53 — most prominently well-differentiated and dedifferentiated liposarcoma (~90% MDM2/CDK4 co-amplification). Excess MDM2 constitutively degrades wild-type p53, phenocopying TP53 mutation. MDM2 inhibitors (navtemadlin, milademetan) show single-agent responses in MDM2-amplified AML and liposarcoma with wild-type TP53.
Database References
Key Pathways
- ·p53 signaling pathway
- ·Ubiquitin-mediated proteolysis
- ·Apoptosis regulation
Disease Associations
- ·Soft tissue sarcoma
- ·Osteosarcoma
- ·Acute myeloid leukemia
Research Activity
MDM2 is an actively studied target: about 10+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track MDM2 trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About MDM2
What does MDM2 do?
MDM2 is an E3 ubiquitin ligase that polyubiquitinates p53, targeting it for proteasomal degradation, and also directly inhibits p53's transcriptional activation domain. Together these mechanisms form the principal p53 negative feedback loop: p53 activates MDM2, which then degrades p53.
How does MDM2 amplification cause cancer without TP53 mutation?
MDM2 amplification leads to excess MDM2 protein that constitutively degrades wild-type p53, functionally inactivating the p53 pathway without requiring TP53 mutation. MDM2-amplified tumours — particularly liposarcomas — therefore retain wild-type TP53 and are rational targets for MDM2 inhibitors.
Are there drugs targeting MDM2?
MDM2 inhibitors (idasanutlin, milademetan, navtemadlin) occupy the p53-binding pocket of MDM2, blocking the protein-protein interaction and stabilising p53. Clinical trials are ongoing in MDM2-amplified liposarcoma and AML, where responses in TP53-wild-type patients have been observed.